Ionis Pharmaceuticals, Inc(IONS)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

IONS Ionis Pharmaceuticals, Inc

休市中 02-27 16:00:00 EST

81.15

+0.55

+0.68%

盘后81.15

+0.000.00%

19:53 EST

最高82.10	最低80.06	成交量277.37万
今开80.59	昨收80.60	日振幅2.53%
总市值134.05亿	流通市值133.09亿	总股本1.65亿
成交额2.25亿	换手率1.69%	流通股本1.64亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"IONS","market":"US","secType":"STK","nameCN":"Ionis Pharmaceuticals, Inc","latestPrice":81.15,"timestamp":1772226000000,"preClose":80.6,"halted":0,"volume":2773689,"hourTrading":{"tag":"盘后","latestPrice":81.15,"preClose":81.15,"latestTime":"19:53 EST","volume":240072,"amount":19481814.3392,"timestamp":1772240032775,"change":0,"changeRate":0,"amplitude":0.004313},"delay":0,"changeRate":0.006823821339950514,"floatShares":164000000,"shares":165192011,"eps":-2.38,"marketStatus":"休市中","change":0.55,"latestTime":"02-27 16:00:00 EST","open":80.59,"high":82.1,"low":80.06,"amount":225346781.80227,"amplitude":0.02531,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.38,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1772442000000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":80.6,"preHourTrading":{"tag":"盘前","latestPrice":80.53,"preClose":80.6,"latestTime":"09:29 EST","volume":194,"amount":15623.09936,"timestamp":1772202599999,"change":-0.07,"changeRate":-0.000868,"amplitude":0.000868},"postHourTrading":{"tag":"盘后","latestPrice":81.15,"preClose":81.15,"latestTime":"19:53 EST","volume":240072,"amount":19481814.3392,"timestamp":1772240032775,"change":0,"changeRate":0,"amplitude":0.004313},"volumeRatio":1.033121829076755,"impliedVol":0.3905,"impliedVolPercentile":0.2271},"requestUrl":"/m/hq/s/IONS","defaultTab":"news","newsList":[{"id":"1189414337","title":"Ionis制药公司获FDA设定处方药用户费用法案目标行动日期为2026年6月30日","url":"https://stock-news.laohu8.com/highlight/detail?id=1189414337","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1189414337?lang=zh_cn&edition=full","pubTime":"2026-02-26 20:03","pubTimestamp":1772107408,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局（FDA）已为Ionis制药公司（Ionis Pharmaceuticals, Inc）设定了一项关键监管节点——根据处方药用户费用法案（Pdufa），其目标行动日期定为2026年6月30日。\n这一日期标志着FDA完成对该公司相关药物申请审查的最终期限。该时间表的确定，为Ionis制药的研发进程提供了明确的监管时间框架，也预示着其新药审批流程进入倒计时阶段。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IONS","BK4139"],"gpt_icon":0},{"id":"1164552946","title":"异动解读 | 预测2026年收入低于预期，Ionis Pharmaceuticals盘前大跌9.54%","url":"https://stock-news.laohu8.com/highlight/detail?id=1164552946","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1164552946?lang=zh_cn&edition=full","pubTime":"2026-02-25 20:40","pubTimestamp":1772023241,"startTime":"0","endTime":"0","summary":"生物制药公司Ionis Pharmaceuticals  今日盘前股价大幅下跌9.54%，引起了市场的广泛关注。消息面上，该公司发布了最新的财务预测，预计2026年收入将在8亿至8.25亿美元之间，这一数字低于华尔街分析师平均预期的9.02亿美元。市场分析认为，对未来收入增长的保守预期是导致投资者信心受挫、股价在盘前交易时段承压下跌的主要原因。公司旗下遗传疾病药物Tryngolza在第四季度销售额达到5000万美元，环比增长56%，显示出良好的产品势头，但未能抵消市场对远期财务表现的担忧。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["IONS"],"gpt_icon":0},{"id":"1173104180","title":"财报前瞻｜Ionis Pharmaceuticals, Inc本季度营收预计增13.44%，欧洲获批与里程碑进度牵动预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1173104180","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1173104180?lang=zh_cn&edition=full","pubTime":"2026-02-18 10:47","pubTimestamp":1771382875,"startTime":"0","endTime":"0","summary":"Ionis Pharmaceuticals, Inc将于2026年02月25日发布最新季度财报，市场关注商业板块增速、管线里程碑兑现与费用节奏的平衡。市场一致预期本季度Ionis Pharmaceuticals, Inc营收预计为1.56亿美元，同比增加13.44%；调整后每股收益预计为-1.32美元，同比下降17.63%；息税前利润预计为-2.10亿美元，同比下降19.11%；公司上季度并未在公开口径给出明确的季度营收或EPS指引。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜Ionis Pharmaceuticals, Inc本季度营收预计增13.44%，欧洲获批与里程碑进度牵动预期","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IONS"],"gpt_icon":0},{"id":"1191518855","title":"Ionis Pharmaceuticals, Inc 有望获得1500万美元里程碑付款及高达30%的净销售额分层特许权使用费","url":"https://stock-news.laohu8.com/highlight/detail?id=1191518855","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1191518855?lang=zh_cn&edition=full","pubTime":"2026-01-21 20:04","pubTimestamp":1768997079,"startTime":"0","endTime":"0","summary":"Ionis Pharmaceuticals, Inc 近日迎来重大利好消息。根据最新合作协议条款，该公司已具备资格获取一笔高达1500万美元的里程碑付款。更值得关注的是，其特许权使用费结构将采用分层模式，最高可达产品净销售额的30%。这一商业安排凸显了Ionis Pharmaceuticals核心产品的市场潜力。对于Ionis Pharmaceuticals而言，这笔潜在收益将为其研发管线注入新的资金支持，同时强化公司在罕见病和精准医疗领域的战略布局。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IONS"],"gpt_icon":0},{"id":"1145314898","title":"渤健公司获欧盟委员会批准Spiranza®高剂量方案用于脊髓性肌萎缩症治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=1145314898","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1145314898?lang=zh_cn&edition=full","pubTime":"2026-01-13 00:11","pubTimestamp":1768234293,"startTime":"0","endTime":"0","summary":"欧盟委员会已正式批准渤健公司针对脊髓性肌萎缩症的Spiranza®（Nusinersen）高剂量治疗方案。这一监管里程碑标志着该疗法在欧盟市场获得重要拓展，为患者群体提供更具灵活性的用药选择。\n此次获批的高剂量方案将进一步提升药物在临床实践中的应用价值，凸显渤健公司在神经科学治疗领域持续创新的战略布局。监管机构的认可也为该疗法在更广泛患者群体中的使用铺平道路。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0234570918.USD","BK4588","BK4139","BK4532","IONS","LU0320765992.SGD","IE00B894F039.SGD","BK4585","BIIB","LU0109394709.USD","BK4533","IE00B19Z9P08.USD","IE00B19Z9Z06.USD","LU0889565916.HKD"],"gpt_icon":0},{"id":"1137439537","title":"Ionis合作伙伴葛兰素史克公布Bepirovirsen三期研究B-Well 1和B-Well 2积极顶线结果 该药物有望成为慢性乙肝首创疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=1137439537","media":"美股速递","labels":["corporation","productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1137439537?lang=zh_cn&edition=full","pubTime":"2026-01-07 15:18","pubTimestamp":1767770330,"startTime":"0","endTime":"0","summary":"Ionis Pharmaceuticals, Inc的合作伙伴葛兰素史克宣布，其针对慢性乙型肝炎的潜在首创药物Bepirovirsen，在三期临床研究B-Well 1和B-Well 2中取得了积极的顶线结果。这项关键进展标志着该疗法在追求功能性治愈慢性乙肝的道路上迈出了重要一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IONS","BK4139"],"gpt_icon":0},{"id":"1172421919","title":"Ionis宣布拟议可转换债券发行以再融资2026年可转换债券","url":"https://stock-news.laohu8.com/highlight/detail?id=1172421919","media":"投资观察","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1172421919?lang=zh_cn&edition=full","pubTime":"2025-11-20 01:25","pubTimestamp":1763573107,"startTime":"0","endTime":"0","summary":"11月12日消息 - Ionis Pharmaceuticals Inc ::*IONIS宣布拟议可转换债券发行以再融资2026年可转换债券*IONIS PHARMACEUTICALS INC - 将发行7亿美元可转换债券，到期时间为2030年*IONIS PHARMACEUTICALS INC - 授予额外7000万美元债券的选择权","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IONS"],"gpt_icon":0},{"id":"1158847363","title":"Dawnzera™（Donidalorsen）获得CHMP积极意见，推荐在欧盟批准治疗遗传性血管水肿（HAE）","url":"https://stock-news.laohu8.com/highlight/detail?id=1158847363","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1158847363?lang=zh_cn&edition=full","pubTime":"2025-11-14 20:01","pubTimestamp":1763121688,"startTime":"0","endTime":"0","summary":"Dawnzera™（Donidalorsen）获得CHMP的积极意见，建议在欧盟批准用于治疗遗传性血管水肿（HAE）。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IONS"],"gpt_icon":0},{"id":"1159503918","title":"Ionis Pharmaceuticals Inc：定价7亿美元的2030年到期0.00%可转换高级债券","url":"https://stock-news.laohu8.com/highlight/detail?id=1159503918","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1159503918?lang=zh_cn&edition=full","pubTime":"2025-11-13 13:40","pubTimestamp":1763012431,"startTime":"0","endTime":"0","summary":"Ionis Pharmaceuticals Inc：定价7亿美元的2030年到期0.00%可转换高级债券","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IONS","BK4139"],"gpt_icon":0},{"id":"1191555721","title":"Ionis Pharmaceuticals股价在盘后上涨3.2%；宣布拟定可转换债券发行以再融资2026年可转换票据","url":"https://stock-news.laohu8.com/highlight/detail?id=1191555721","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1191555721?lang=zh_cn&edition=full","pubTime":"2025-11-12 05:38","pubTimestamp":1762897106,"startTime":"0","endTime":"0","summary":"Ionis Pharmaceuticals股价在盘后上涨3.2%；宣布拟定可转换债券发行以再融资2026年可转换票据","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IONS"],"gpt_icon":0},{"id":"1172347027","title":"Ionis Pharmaceuticals：预计产品REV将迎来增长，新增合作伙伴REV助力公司在2028年实现现金流持平","url":"https://stock-news.laohu8.com/highlight/detail?id=1172347027","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1172347027?lang=zh_cn&edition=full","pubTime":"2025-10-29 19:11","pubTimestamp":1761736303,"startTime":"0","endTime":"0","summary":"Ionis Pharmaceuticals：预计产品REV将迎来增长，新增合作伙伴REV助力公司在2028年实现现金流持平","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IONS","BK4139"],"gpt_icon":0},{"id":"1123195233","title":"渤健公司将收购Alcyone Therapeutics，为核心产品和管线候选药物扩展药物递送解决方案组合","url":"https://stock-news.laohu8.com/highlight/detail?id=1123195233","media":"美股速递","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1123195233?lang=zh_cn&edition=full","pubTime":"2025-09-18 19:41","pubTimestamp":1758195688,"startTime":"0","endTime":"0","summary":"渤健公司将收购Alcyone Therapeutics，为核心产品和管线候选药物扩展药物递送解决方案组合","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IONS","IE00B894F039.SGD","LU0320765992.SGD","IE00B19Z9Z06.USD","BK4532","BK4533","LU0234570918.USD","IE00B19Z9P08.USD","BK4588","BK4139","BK4585","LU0889565916.HKD","BIIB","LU0109394709.USD"],"gpt_icon":0},{"id":"1135242848","title":"BMO将Ionis Pharmaceuticals评级从市场表现上调至跑赢大盘，目标价从40美元上调至70美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1135242848","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1135242848?lang=zh_cn&edition=full","pubTime":"2025-09-03 19:01","pubTimestamp":1756897303,"startTime":"0","endTime":"0","summary":"BMO将Ionis Pharmaceuticals的评级从市场表现上调至跑赢大盘，同时将目标价从40美元大幅上调至70美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IONS","BK4139"],"gpt_icon":0},{"id":"1197561614","title":"Ionis Pharmaceuticals高管表示急性胰腺炎患者平均住院17天，支付方成本高昂","url":"https://stock-news.laohu8.com/highlight/detail?id=1197561614","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1197561614?lang=zh_cn&edition=full","pubTime":"2025-09-02 21:16","pubTimestamp":1756818976,"startTime":"0","endTime":"0","summary":"Ionis Pharmaceuticals高管表示，急性胰腺炎患者平均住院时间长达17天，这对支付方来说成本非常高昂。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IONS","BK4139"],"gpt_icon":0},{"id":"1180606351","title":"Ionis Pharmaceuticals高管：严重高甘油三酯血症适应症获批时将公布定价","url":"https://stock-news.laohu8.com/highlight/detail?id=1180606351","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1180606351?lang=zh_cn&edition=full","pubTime":"2025-09-02 21:07","pubTimestamp":1756818424,"startTime":"0","endTime":"0","summary":"Ionis Pharmaceuticals公司高管表示，该公司将在其严重高甘油三酯血症治疗适应症获得监管批准时公布相关药物的定价信息。这一表态显示该公司正在为其治疗严重高甘油三酯血症的药物制定市场准入策略。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IONS"],"gpt_icon":0},{"id":"1120167759","title":"Ionis Pharmaceuticals高管表示Olezarsen有潜力为患者提供每月使用自动注射器自我给药的便利性 - 电话会议","url":"https://stock-news.laohu8.com/highlight/detail?id=1120167759","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1120167759?lang=zh_cn&edition=full","pubTime":"2025-09-02 20:56","pubTimestamp":1756817811,"startTime":"0","endTime":"0","summary":"Ionis Pharmaceuticals高管表示Olezarsen有潜力为患者提供每月使用自动注射器自我给药的便利性 - 电话会议","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IONS","BK4139"],"gpt_icon":0},{"id":"1133437325","title":"Ionis Pharmaceuticals：Olezarsen治疗严重高甘油三酯血症患者的关键3期Core和Core2研究获得积极顶线结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1133437325","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1133437325?lang=zh_cn&edition=full","pubTime":"2025-09-02 19:24","pubTimestamp":1756812253,"startTime":"0","endTime":"0","summary":"Ionis Pharmaceuticals宣布，其药物Olezarsen在治疗严重高甘油三酯血症患者的关键3期Core和Core2研究中取得积极的顶线结果。这一研究成果为该公司在代谢性疾病治疗领域的发展提供了重要支撑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IONS","BK4139"],"gpt_icon":0},{"id":"1123660220","title":"Ionis Pharmaceuticals：Olezarsen达到减少急性胰腺炎事件的次要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=1123660220","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1123660220?lang=zh_cn&edition=full","pubTime":"2025-09-02 19:12","pubTimestamp":1756811553,"startTime":"0","endTime":"0","summary":"Ionis Pharmaceuticals：Olezarsen达到减少急性胰腺炎事件的次要终点","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IONS","BK4139"],"gpt_icon":0},{"id":"1197389364","title":"Ionis Pharmaceuticals宣布Olezarsen三期临床研究取得积极结果 - SEC文件","url":"https://stock-news.laohu8.com/highlight/detail?id=1197389364","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1197389364?lang=zh_cn&edition=full","pubTime":"2025-09-02 19:08","pubTimestamp":1756811300,"startTime":"0","endTime":"0","summary":"Ionis Pharmaceuticals宣布其药物Olezarsen的三期临床研究取得积极结果，该消息通过SEC文件披露。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IONS"],"gpt_icon":0},{"id":"2518070452","title":"Ionis Pharmaceuticals, Inc.盘中异动 大幅下挫5.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518070452","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518070452?lang=zh_cn&edition=full","pubTime":"2025-03-11 02:53","pubTimestamp":1741632820,"startTime":"0","endTime":"0","summary":"北京时间2025年03月11日02时53分，Ionis Pharmaceuticals, Inc.股票出现波动，股价快速下挫5.00%。Ionis Pharmaceuticals, Inc.股票所在的生物技术行业中，整体涨幅为0.60%。Ionis Pharmaceuticals, Inc.公司简介：Ionis Pharmaceuticals 是利用反义技术发现和开发新型药物的领先开发商。Ionis 于 2024 年获得 FDA 批准，用于治疗罕见的高甘油三酯综合征的 Tryngolza，标志着其首次独立上市。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250311025340abf37261&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250311025340abf37261&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","IONS"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ionis.com","stockEarnings":[{"period":"1week","weight":-0.0241},{"period":"1month","weight":-0.0094},{"period":"3month","weight":-0.0191},{"period":"6month","weight":0.9034},{"period":"1year","weight":1.5885},{"period":"ytd","weight":0.0258}],"compareEarnings":[{"period":"1week","weight":-0.005},{"period":"1month","weight":-0.0136},{"period":"3month","weight":0.0038},{"period":"6month","weight":0.0635},{"period":"1year","weight":0.1725},{"period":"ytd","weight":0.006}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"伊奥尼斯制药公司于1989年在加利福尼亚州注册成立，并于1991年1月将公司注册州变更为特拉华州。该公司花了三十年时间开拓RNA靶向药物，并已发展成为一家完全整合的商业阶段生物技术公司，拥有七种已上市药物，并拥有横跨神经病学、心脏代谢疾病和其他患者高需求领域的强大管道。它继续通过独立和合作开发推进下一代RNA靶向技术，为患有严重疾病的患者提供创新疗法。","yearOnYearQuotes":[{"month":1,"riseRate":0.636364,"avgChangeRate":-0.020204},{"month":2,"riseRate":0.454545,"avgChangeRate":-0.015383},{"month":3,"riseRate":0.3,"avgChangeRate":-0.028033},{"month":4,"riseRate":0.4,"avgChangeRate":0.018094},{"month":5,"riseRate":0.4,"avgChangeRate":-0.049558},{"month":6,"riseRate":0.8,"avgChangeRate":0.059464},{"month":7,"riseRate":0.8,"avgChangeRate":0.041363},{"month":8,"riseRate":0.5,"avgChangeRate":0.012224},{"month":9,"riseRate":0.5,"avgChangeRate":0.051342},{"month":10,"riseRate":0.2,"avgChangeRate":-0.026479},{"month":11,"riseRate":0.6,"avgChangeRate":0.097251},{"month":12,"riseRate":0.4,"avgChangeRate":0.002194}],"exchange":"NASDAQ","name":"Ionis Pharmaceuticals, Inc","nameEN":"Ionis Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Ionis Pharmaceuticals, Inc(IONS)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Ionis Pharmaceuticals, Inc(IONS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Ionis Pharmaceuticals, Inc,IONS,Ionis Pharmaceuticals, Inc股票,Ionis Pharmaceuticals, Inc股票老虎,Ionis Pharmaceuticals, Inc股票老虎国际,Ionis Pharmaceuticals, Inc行情,Ionis Pharmaceuticals, Inc股票行情,Ionis Pharmaceuticals, Inc股价,Ionis Pharmaceuticals, Inc股市,Ionis Pharmaceuticals, Inc股票价格,Ionis Pharmaceuticals, Inc股票交易,Ionis Pharmaceuticals, Inc股票购买,Ionis Pharmaceuticals, Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Ionis Pharmaceuticals, Inc(IONS)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Ionis Pharmaceuticals, Inc(IONS)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}